aTyr Pharma, Inc. (ATYR)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
0.17 USD
-0.01
(-5.332%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 0.18 +0.00 (0.575%) ⇧ (Oct. 16, 2026, 7:12 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 5:13 a.m. EDT
The investment case for aTyr Pharma is currently paralyzed by a severe credibility crisis and deteriorating operational reality. While the balance sheet remains technically solvent with a fortress-like current ratio, the business fundamentals are in freefall: revenue is negligible ($190k), losses are widening, and the company has just executed a brutal 60% workforce reduction, signaling a desperate attempt to survive rather than grow. The stock has lost 97.5% of its value over the last nine years, reflecting a market that has thoroughly priced out the risk of this biotech venture failing. Although the options chain shows speculative bets on a miraculous turnaround via the efzofitimod program, the recent news of a 60% staff cut and FDA protocol feedback looms as a massive overhang. The statistical forecast models correctly identify a weak downward bias, confirming that without a definitive, positive clinical readout, the path of least resistance remains sharply lower. Until the company can demonstrate sustained revenue growth and a stabilized workforce, this remains a high-risk speculative vehicle rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.329242 |
| MSTL | 0.341249 |
| AutoETS | 0.355784 |
| AutoTheta | 0.364638 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 203.97 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.150 |
| Excess Kurtosis | -0.62 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 23.252 |
| Revenue per Share | 0.002 |
| Market Cap | 17,067,212 |
| Forward P/E | -0.37 |
| Beta | 0.91 |
| Website | https://atyrpharma.com |
As of Oct. 10, 2026, 5:13 a.m. EDT: Options activity reveals a distinct 'long gamma' setup with heavy open interest in out-of-the-money calls (strikes $1.00 to $7.00) and significant put volume concentrated at the $2.00-$2.50 strikes. This structure suggests speculators are positioning for a binary event—likely the upcoming Phase 3 trial results—that could drive a massive gap up, while simultaneously hedging against a catastrophic failure that would keep the stock near current lows. The lack of in-the-money call volume indicates the market currently views the probability of immediate recovery as low, despite the asymmetric payoff potential.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.81960785 |
| Address1 | 10,240 Sorrento Valley Road |
| Address2 | Suite 300 |
| All Time High | 396.06 |
| All Time Low | 0.181 |
| Ask | 0.2082 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,913,920 |
| Average Daily Volume3 Month | 3,234,993 |
| Average Volume | 3,234,993 |
| Average Volume10Days | 1,913,920 |
| Beta | 0.913 |
| Bid | 0.175 |
| Bid Size | 5 |
| Board Risk | 5 |
| Book Value | 0.497 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.174 |
| Current Ratio | 5.121 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.1911 |
| Day Low | 0.174 |
| Debt To Equity | 23.252 |
| Display Name | aTyr Pharma |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,741,899,600 |
| Earnings Call Timestamp Start | 1,741,899,600 |
| Earnings Timestamp | 1,786,132,800 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -63,197,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.463 |
| Enterprise To Revenue | -153.925 |
| Enterprise Value | -29,245,788 |
| Eps Current Year | -0.41333 |
| Eps Forward | -0.46857 |
| Eps Trailing Twelve Months | -0.62 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 858 731 8394 |
| Fifty Day Average | 0.4122 |
| Fifty Day Average Change | -0.23820001 |
| Fifty Day Average Change Percent | -0.57787484 |
| Fifty Two Week Change Percent | -81.960785 |
| Fifty Two Week High | 1.11 |
| Fifty Two Week High Change | -0.936 |
| Fifty Two Week High Change Percent | -0.84324324 |
| Fifty Two Week Low | 0.174 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.174 - 1.11 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,431,005,400,000 |
| Float Shares | 97,743,138 |
| Forward Eps | -0.46857 |
| Forward P E | -0.3713426 |
| Free Cashflow | -31,708,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 58 |
| Fullday Change | -0.0088 |
| Fullday Change Percent | -4.7878127 |
| Fullday Price | 0.174 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -46,896,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0031299999 |
| Held Percent Institutions | 0.36238998 |
| Implied Shares Outstanding | 98,087,425 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,561,939,200 |
| Last Split Factor | 1:14 |
| Long Business Summary | aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California. |
| Long Name | aTyr Pharma, Inc. |
| Market | us_market |
| Market Cap | 17,067,212 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_33940575 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -60,807,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 36,694,505 |
| Number Of Analyst Opinions | 7 |
| Open | 0.189 |
| Operating Cashflow | -54,540,000 |
| Operating Margins | -336.09473 |
| Overall Risk | 6 |
| Phone | 858 731 8389 |
| Post Market Change | 0.001000002 |
| Post Market Change Percent | 0.5747138 |
| Post Market Price | 0.175 |
| Post Market Time | 1,792,192,323 |
| Previous Close | 0.1838 |
| Price Eps Current Year | -0.42097113 |
| Price Hint | 4 |
| Price To Book | 0.35010058 |
| Price To Sales Trailing12 Months | 89.82743 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.076 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0098 |
| Regular Market Change Percent | -5.33188 |
| Regular Market Day High | 0.1911 |
| Regular Market Day Low | 0.174 |
| Regular Market Day Range | 0.174 - 0.1911 |
| Regular Market Open | 0.189 |
| Regular Market Previous Close | 0.1838 |
| Regular Market Price | 0.174 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 1,801,645 |
| Return On Assets | -0.46582 |
| Return On Equity | -0.98680997 |
| Revenue Per Share | 0.002 |
| Sand P52 Week Change | 0.14980114 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 98,087,425 |
| Shares Percent Shares Out | 0.1314 |
| Shares Short | 12,893,008 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,279,033 |
| Short Name | aTyr Pharma, Inc. |
| Short Percent Of Float | 0.1319 |
| Short Ratio | 1.72 |
| Source Interval | 15 |
| State | CA |
| Symbol | ATYR |
| Target High Price | 7.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 2.85714 |
| Target Median Price | 3.0 |
| Total Cash | 57,418,000 |
| Total Cash Per Share | 0.585 |
| Total Debt | 11,299,000 |
| Total Revenue | 190,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.62 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.636585 |
| Two Hundred Day Average Change | -0.462585 |
| Two Hundred Day Average Change Percent | -0.7266665 |
| Type Disp | Equity |
| Volume | 1,801,645 |
| Website | https://atyrpharma.com |
| Zip | 92,121 |